Allworth Financial LP Invests $2.36 Million in Supernus Pharmaceuticals, Inc. $SUPN

Allworth Financial LP acquired a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 50,669 shares of the specialty pharmaceutical company's stock, valued at approximately $2,357,000. Allworth Financial LP owned about 0.09% of Supernus Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Supernus Pharmaceuticals during the second quarter worth approximately $434,871,000. State Street Corp grew its position in Supernus Pharmaceuticals by 1.4% during the 4th quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company's stock worth $110,296,000 after purchasing an additional 31,668 shares during the last quarter. Geode Capital Management LLC grew its position in Supernus Pharmaceuticals by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company's stock worth $73,215,000 after purchasing an additional 62,875 shares during the last quarter. Loomis Sayles & Co. L P increased its stake in Supernus Pharmaceuticals by 12.7% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,448,842 shares of the specialty pharmaceutical company's stock valued at $72,007,000 after purchasing an additional 162,905 shares during the period. Finally, Stephens Investment Management Group LLC increased its stake in Supernus Pharmaceuticals by 4.5% in the fourth quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company's stock valued at $69,904,000 after purchasing an additional 61,120 shares during the period.

Analyst Ratings Changes

Several research firms have commented on SUPN. Cantor Fitzgerald upped their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an "overweight" rating in a research note on Thursday, July 9th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Zacks Research raised shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 6th. Finally, Weiss Ratings reiterated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Supernus Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $62.83.

Supernus Pharmaceuticals Price Performance

NASDAQ SUPN opened at $45.85 on Friday. Supernus Pharmaceuticals, Inc. has a 12 month low of $42.45 and a 12 month high of $59.68. The company has a 50-day moving average of $46.74 and a 200-day moving average of $48.82. The company has a market cap of $2.67 billion, a P/E ratio of -23.88, a P/E/G ratio of 0.87 and a beta of 0.56.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last released its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of $0.42 by ($1.43). The firm had revenue of $219.06 million for the quarter, compared to analyst estimates of $205.31 million. Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The company's quarterly revenue was up 32.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.40 earnings per share. As a group, equities research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source